BiologicsHQ Search
Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book and FDA-approved cellular and gene therapy products. Product and Company page search results are reported for FDA-approved indications, aBLA and 505(b)(2) activity, approved foreign biosimilars, IPRs, PGRs and U.S. litigations.
Biocon Announces Launch of EYLEA® Interchangeable Biosimilar Yesafili™ While PGR Denied Institution
Robert S. Schwartz, Ph.D.
READ MORE
Fresenius Kabi and Dr. Reddy’s Announce Rituxan® Biosimilar Zimrixby™ (rituximab-cdxx) FDA Approval
Robert S. Schwartz, Ph.D.
READ MORE
